Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Theravance |
---|---|
Information provided by: | Theravance |
ClinicalTrials.gov Identifier: | NCT00077675 |
Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. This study will measure how well TD-6424 can control infections and whether the drug is safe to give to patients.
Condition | Intervention | Phase |
---|---|---|
Infections, Gram-Positive Bacterial |
Drug: TD-6424 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase 2, Randomized, Double Blind, Multinational Trial of Intravenous TD 6424 Versus Standard Therapy for Treatment of Complicated Gram Positive Skin and Skin Structure Infections |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Patients must have a diagnosis of one of the following complicated skin and soft tissue infections and either a suspected or confirmed Gram positive organism
Study ID Numbers: | I6424-202b, FAST 2 |
Study First Received: | February 10, 2004 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00077675 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Abscess Burns Cellulitis Ulcer Wound infections |
Bacterial Infections Burns Gram-Positive Bacterial Infections Cellulitis |
Ulcer Abscess Wound Infection |
Bacterial Infections Communicable Diseases Gram-Positive Bacterial Infections Infection |